PD-L1-Positive Lung Non-Small Cell Carcinoma

PD-L1-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 0
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: —
Top sponsor: —
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04203485	Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)	unknown	Phase 3	762	Jiangsu HengRui Medicine Co., Ltd.INDUSTRY	0	May 8, 2020	clinicaltrials

Data updated 23 days agoSource updated May 8, 2020source: clinicaltrials